Atabecestat

Description: Atabecestat (JNJ-54861911) is a potent, brain-penetrant, and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor that achieves robust and high CSF Abeta reduction, is well-tolerated, and displays sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat (JNJ-54861911) has the potential for Alzheimer's Disease treatment[1]. Target: BACE. Smiles: C[C@]1(C=CSC(N)=N1)c1cc(NC(=O)c2ccc(cn2)C#N)ccc1F. References: Timmers M, et al. Profiling the dynamics of CSF and plasma Abeta reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor.Alzheimers Dement (N Y). 2016 Aug 24,2(3):202-212.